Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MCM Negotiates Partnership with Clearstone of Canada in CLS Services
April 18, 2011
- Ajinomoto Obtains Domestic Rights to IBD Treatment from Dr Falk
April 18, 2011
- NEW PRODUCTS
April 18, 2011
- FDA Approves HCC Test System μTASWako i30: Wako Pure Chemical
April 18, 2011
- BioWa Licenses Potelligent to OBT
April 18, 2011
- Takeda, Heptares of UK Announce 2-Year Research Collaboration
April 18, 2011
- Eisai's Subsidiary Morphotek Acquires Tumor Targeting Assets from TransMolecular
April 18, 2011
- Sanofi-aventis Acquires Additional Nichi-Iko Shares
April 18, 2011
- BI 201335 NA Shows Favorable Results for Hepatitis C in PIIb: BI
April 18, 2011
- Disaster to Have No Long-term Impact on Japan Business: Chairman Barner of BI
April 18, 2011
- Hisamitsu: Acquisition of Noven Contributes to Growth in Sales
April 18, 2011
- Council Beefs Up Activities to Improve Environment for Drug Discovery in Osaka
April 18, 2011
- Operating, Net Losses Decrease: MediciNova
April 18, 2011
- Motesanib Fails to Increase OS in Non-SCC NSCLC in PIII
April 18, 2011
- Eisai Enters Collaborative R&D Agreement with PRISM BioLab
April 11, 2011
- BI Japan Starts Operations
April 11, 2011
- Collategene Shrinks Ulcers in Buerger's Disease Patients: AnGes MG
April 11, 2011
- Astellas Licenses 3 Compounds to Cardeus
April 11, 2011
- Actos's Use Patent Valid for Combination with α-GIs, SUs, But Not BGs
April 11, 2011
- Mirabegron Improves Key OAB Symptoms in PIII Trial: Astellas
April 11, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…